Evidence map›Paper›PMID 41300843›Full record

ReviewGenes2025

Reprogramming Fibrosis: How Protein PTMs Reshape the IPF Proteome.

Yunze Li, Wei Kong, Hanqi Zhang, Xinfeng Wei, Junxuan Yi, Mingwei Wang, Shunzi Jin, Duo Yu

Abstract readReview
In one paragraph

Review in Genes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yunze LiNHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Changchun 130012, China.ORCID 0009-0004-8826-906X
Wei KongNHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Changchun 130012, China.
Hanqi ZhangDepartment of Radiotherapy, China-Japan Union Hospital of Jilin University, Changchun 130033, China.
Xinfeng WeiNHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Changchun 130012, China.
Junxuan YiNHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Changchun 130012, China.ORCID 0000-0002-4398-1836
Mingwei WangNHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Changchun 130012, China.
Shunzi JinNHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Changchun 130012, China.
Duo YuDepartment of Radiotherapy, China-Japan Union Hospital of Jilin University, Changchun 130033, China.

Funding

National Natural Science Foundation of China 82404194
6 · The paper itself

Abstract

Idiopathic pulmonary fibrosis (IPF) is a fatal and progressive lung disorder. Its pathological process involves persistent epithelial damage, ongoing inflammation, and dysregulated tissue repair. Currently, there are no effective treatment methods to improve patient survival. However, post-translational modifications (PTMs) have gradually garnered widespread attention. They are the processes by which various chemical groups are added to or removed from proteins' amino acid side chains or the N- or C-terminal ends of the polypeptide chain following synthesis. Additionally, they can regulate the energy supply of cells, regulate the cell cycle, and affect important signaling pathways such as TGF-β. This review systematically summarizes different categories of PTMs, organizes the PTMs involved in various injury stages of IPF, outlines the roles of different cells throughout the process, and analyzes future clinical diagnosis and treatment strategies as well as intervention targets for IPF, providing guiding significance for the systematic intervention of IPF in the future.

Indexed as

Idiopathic Pulmonary FibrosisProtein Processing, Post-TranslationalProteomeAnimalsHumansSignal TransductionTransforming Growth Factor betaProteomeTransforming Growth Factor betaidiopathic pulmonary fibrosislung injurymacro-phagespost-translational modificationstherapeutic strategies

Identifiers

PMID41300843
PMCPMC12652984

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.